Oppenheimer has upgraded Inspire Medical Systems Inc (INSP) to an Outperform rating from Perform, effective December 7, 2025. This shift signals a more favorable outlook on the company's future performance.
Inspire Medical Systems, headquartered in Golden Valley, Minnesota, specializes in innovative, minimally invasive solutions for patients suffering from obstructive sleep apnea. Its proprietary Inspire therapy is FDA, EU MDR, and PDMA-approved, offering a safe and effective treatment for moderate to severe cases of this condition. The company currently employs 1,246 individuals and went public on May 3, 2018.
As of December 4, 2025, Inspire Medical Systems boasts a market capitalization of $4.1 billion, a P/E ratio of 92.15, and an EPS of 1.47. The upcoming earnings report is scheduled for August 3, 2026, with an estimated EPS of $0.36 and revenue forecasted at $248.9 million. Recent earnings performance has shown significant surprises, including a 271.7% surprise in Q3 2025, where the EPS reached $0.34 against an estimate of -$0.20.
The upgrade may reflect improved fundamentals or increased confidence in the company’s strategic direction, which includes a focus on expanding its sales efforts among ear, nose, and throat physicians and sleep centers. Analyst ratings serve as one of many tools investors can use to gauge market sentiment, but they should consider various factors, including company fundamentals and industry trends, before making investment decisions.
As of December 1, 2025, the analyst consensus for Inspire Medical Systems is categorized as a Buy, with 6 Strong Buy, 13 Buy, and 7 Hold ratings among 26 total assessments. This update provides insight into the evolving analyst sentiment surrounding Inspire Medical Systems and its growth potential in the health care sector.